This slide deck, presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health provides the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more!

This slide deck created by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. 

This slide deck created by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). 

This slide deck will features insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity created by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine.

This slide deck created by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease.

This case-based slide deck, created by Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will show how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Start the activity now.

This slide deck, part of a two-part series, led by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition. Part 1 of this series will take an in-depth look at the new standards in multiple myeloma classification at diagnosis, recent data on treatment regimens for newly diagnosed disease, and strategies for maintenance therapy. 

This slide deck, part of a two-part series, led by by Sarah A. Holstein, MD, PhD, and Ashley E. Rosko, MD, will explore expert perspectives on practice-changing developments in the management of multiple myeloma and will also include updates from the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition.

Part 2 will familiarize practitioners with indications of multiple myeloma progression and timing of therapy, highlight practice-changing trials in the early and late relapse settings, and discuss how approaches to relapsed/refractory multiple myeloma are changing based on emerging data. 

This slide deck, developed by Ulka N. Vaishampayan, MD, Professor of Oncology, Wayne State University, highlights evidence-based management of nonmetastatic and metastatic castration-resistant prostate cancer.